Terns Pharmaceuticals Inc. Reveals Presentation Highlighting Upcoming Clinical Data for CML and Obesity Treatments

Reuters

2025/06/06

Terns Pharmaceuticals Inc. Reveals Presentation Highlighting Upcoming Clinical Data for CML and Obesity Treatments

Terns Pharmaceuticals Inc., trading on NASDAQ under the symbol TERN, has released a corporate presentation highlighting its progress as of June 2025. The company is advancing two differentiated clinical assets, TERN-701 and TERN-601, with significant milestones anticipated in the fourth quarter of 2025. TERN-701, an allosteric BCR-ABL inhibitor, aims to address chronic myeloid leukemia $(CML.UK)$ in a market exceeding $5 billion. Meanwhile, TERN-601, an oral GLP-1 receptor agonist, targets obesity with potential competitive weight loss and superior tolerability. Both programs are progressing through clinical trials, with TERN-701 in Phase 1 and TERN-601 in Phase 2. Terns Pharmaceuticals has secured a cash runway of $334 million to support its development pipeline into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541850983"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541850983\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541850983?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-06 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541850983","market":"us","top_or_hot":-1,"title":"Terns Pharmaceuticals Inc. Reveals Presentation Highlighting Upcoming Clinical Data for CML and Obesity Treatments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Terns Pharmaceuticals Inc. Reveals Presentation Highlighting Upcoming Clinical Data for CML and Obesity Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Terns Pharmaceuticals Inc., trading on NASDAQ under the symbol TERN, has released a corporate presentation highlighting its progress as of June 2025. The company is advancing two differentiated clinical assets, TERN-701 and TERN-601, with significant milestones anticipated in the fourth quarter of 2025. TERN-701, an allosteric BCR-ABL inhibitor, aims to address chronic myeloid leukemia <a href=\"https://laohu8.com/S/CML.UK\">$(CML.UK)$</a> in a market exceeding $5 billion. Meanwhile, TERN-601, an oral GLP-1 receptor agonist, targets obesity with potential competitive weight loss and superior tolerability. Both programs are progressing through clinical trials, with TERN-701 in Phase 1 and TERN-601 in Phase 2. Terns Pharmaceuticals has secured a cash runway of $334 million to support its development pipeline into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Terns Pharmaceuticals Inc. Reveals Presentation Highlighting Upcoming Clinical Data for CML and Obesity Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTerns Pharmaceuticals Inc. Reveals Presentation Highlighting Upcoming Clinical Data for CML and Obesity Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-06 20:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Terns Pharmaceuticals Inc. Reveals Presentation Highlighting Upcoming Clinical Data for CML and Obesity Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Terns Pharmaceuticals Inc., trading on NASDAQ under the symbol TERN, has released a corporate presentation highlighting its progress as of June 2025. The company is advancing two differentiated clinical assets, TERN-701 and TERN-601, with significant milestones anticipated in the fourth quarter of 2025. TERN-701, an allosteric BCR-ABL inhibitor, aims to address chronic myeloid leukemia <a href=\"https://laohu8.com/S/CML.UK\">$(CML.UK)$</a> in a market exceeding $5 billion. Meanwhile, TERN-601, an oral GLP-1 receptor agonist, targets obesity with potential competitive weight loss and superior tolerability. Both programs are progressing through clinical trials, with TERN-701 in Phase 1 and TERN-601 in Phase 2. Terns Pharmaceuticals has secured a cash runway of $334 million to support its development pipeline into 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TERN","symbol_name":"Terns Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL4NMTJd:1","article_id":"2541850983","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541850983","pubTimestamp":1749214458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Terns Pharmaceuticals Inc., trading on NASDAQ under the symbol TERN, has released a corporate presentation highlighting its progress as of June 2025. The company is advancing two differentiated clinical assets, TERN-701 and TERN-601, with significant milestones anticipated in the fourth quarter of 2025. TERN-701, an allosteric BCR-ABL inhibitor, aims to address chronic myeloid leukemia  in a market exceeding $5 billion. Meanwhile, TERN-601, an oral GLP-1 receptor agonist, targets obesity with potential competitive weight loss and superior tolerability. Both programs are progressing through clinical trials, with TERN-701 in Phase 1 and TERN-601 in Phase 2. Terns Pharmaceuticals has secured a cash runway of $334 million to support its development pipeline into 2028. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Terns Pharmaceuticals Inc.发布演示文稿，重点介绍即将推出的CML和肥胖症治疗临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN":0.9},"content_text":"Terns Pharmaceuticals Inc. Reveals Presentation Highlighting Upcoming Clinical Data for CML and Obesity Treatments\n    \n\n        Terns Pharmaceuticals Inc., trading on NASDAQ under the symbol TERN, has released a corporate presentation highlighting its progress as of June 2025. The company is advancing two differentiated clinical assets, TERN-701 and TERN-601, with significant milestones anticipated in the fourth quarter of 2025. TERN-701, an allosteric BCR-ABL inhibitor, aims to address chronic myeloid leukemia $(CML.UK)$ in a market exceeding $5 billion. Meanwhile, TERN-601, an oral GLP-1 receptor agonist, targets obesity with potential competitive weight loss and superior tolerability. Both programs are progressing through clinical trials, with TERN-701 in Phase 1 and TERN-601 in Phase 2. Terns Pharmaceuticals has secured a cash runway of $334 million to support its development pipeline into 2028. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}